Prime Medicine (PRME) Enterprise Value (2021 - 2025)
Prime Medicine's Enterprise Value history spans 5 years, with the latest figure at -$177.7 million for Q4 2025.
- For Q4 2025, Enterprise Value rose 5.21% year-over-year to -$177.7 million; the TTM value through Dec 2025 reached -$177.7 million, up 5.21%, while the annual FY2025 figure was -$177.7 million, 5.21% up from the prior year.
- Enterprise Value reached -$177.7 million in Q4 2025 per PRME's latest filing, up from -$208.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$48.8 million in Q3 2023 to a low of -$286.1 million in Q4 2022.
- Average Enterprise Value over 5 years is -$156.1 million, with a median of -$167.4 million recorded in 2022.
- The largest YoY upside for Enterprise Value was 70.04% in 2024 against a maximum downside of 249.8% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$117.7 million in 2021, then plummeted by 142.99% to -$286.1 million in 2022, then skyrocketed by 59.38% to -$116.2 million in 2023, then plummeted by 61.29% to -$187.4 million in 2024, then rose by 5.21% to -$177.7 million in 2025.
- Per Business Quant, the three most recent readings for PRME's Enterprise Value are -$177.7 million (Q4 2025), -$208.4 million (Q3 2025), and -$98.3 million (Q2 2025).